PTPI (Petros Pharmaceuticals) Accounts Receivable : $1.95 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Petros Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Petros Pharmaceuticals's accounts receivables for the quarter that ended in Sep. 2024 was $1.95 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Petros Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 was 112.85.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Petros Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-1.15.

Petros Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Petros Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Petros Pharmaceuticals Accounts Receivable Chart

Petros Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

2.61

5.15

2.46

2.11

2.23

Petros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Receivable	Get a 7-Day Free Trial															2.98	2.23	1.96	1.78	1.95

Petros Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Petros Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Petros Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.949	/	1.576	*	91
=	112.85

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Petros Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Petros Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.895	+	0.75 * 1.949	+	0.5 * 1.406	-	17.577
-	0.001	-	0)	/	10.0149
=	-1.15

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Petros Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Petros Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Petros Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petros Pharmaceuticals Inc (NAS:PTPI) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Greg Bradley	director	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
John D Shulman	director, 10 percent owner
Jcp Iii Sm Aiv, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, L.p.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Juggernaut Partners Iii Gp, Ltd.	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Metp Holdings Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Keith Lavan	officer: Chief Financial Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Fady Boctor	officer: Pres. & Chief Comm. Officer	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Andrew Gesek	officer: President, Timm Medical	200 U.S. 9, SUITE 500, MANALAPAN TOWNSHIP NJ 07726
Metuchen Therapeutics, Llc	10 percent owner	5301 WISCONSIN AVE NW, SUITE 570, WASHINGTON DC 20015
Mitchell Arnold	officer: Prin. Acct. Off/Prin. Fin. Off	200 ROUTE 9 NORTH, SUITE 500, MANALAPAN NJ 07726